← Back to Clinical Trials
Recruiting NCT03053791

NCT03053791 Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03053791
Status Recruiting
Phase
Sponsor University of Zurich
Condition Spinal Cord Injury
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2018-03-15
Primary Completion 2026-12

Trial Parameters

Condition Spinal Cord Injury
Sponsor University of Zurich
Study Type INTERVENTIONAL
Phase N/A
Enrollment 5
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2018-03-15
Completion 2026-12
Interventions
Deep brain stimulation in mesencephalic locomotor regionImplantation of a Deep brain stimulation system

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.

Eligibility Criteria

Inclusion Criteria: 1. Informed Consent 2. Participation in two assessment sessions before enrollment (Screening and baseline) 3. Willingness and ability to comply with the protocol and to attend required study training and visits 4. Male or female subjects 5. Age 18-75 6. Motor incomplete SCI 7. Level of lesion: T10 and above, based on AIS level, preservation of sacral function 8. Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor) 9. Minimum 3 months of recovery after SCI, maximum 2 years after trauma 10. Completed in-patient rehabilitation program 11. WISCI II, level \>2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters 12. Stable medical and physical condition. 13. Adequate care-giver support and access to appropriate medical care in patient's home community Exclusion Criteria: 1. Enrollment of the investigator, his/her family members, employees and other dependent person

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology